New Medical Drug Management Policy

Covers case‑by‑case approval for newly FDA‑approved drugs or new FDA‑approved indications treating chronic/complex non‑cancer diseases (excludes cancer and any non‑FDA or inadequately evidenced uses). Key requirements: FDA‑approved indication with Phase III or Phase IIb (single‑center) trial evidence, no prescribing‑information contraindications, submission of required labs/tests, documented prior therapy failure when required, safe combination use per labeling, and documentation/dosing consistent with the prescribing information.

"All supporting laboratory or test results required in the prescribing information, if applicable."

Sign up to see full coverage criteria, indications, and limitations.